Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc > About the $5.00/vial estimate...

<< Previous

Bullboard Posts

Next >>

Comment by Methodon Jan 31, 2021 11:46pm

149 Views

Post# 32433873

RE:RE:RE:About the $5.00/vial estimate...

I believe in that interview, $12m was coming from VTM (based on the 50k/wk inital indicated order), $12m from antigens (assuming somewhat back to normal testing i.e. 2019 run rate) and $12m from QAPs.

It sounded like it was their low end target from the various presentations I have listened to from Cameron.

lscfa wrote:
Inconsistent with interview on dec 22/2020 where CEO says at end of 2021 the run rate rev will be $36 million.

buddyboybruce wrote: Microbix CEO Cameron Groome states $6 per vial.
The slide in his presentation reads "$4-6 per vial".

Source: 18:30 mark in the following webcast
https://www.youtube.com/watch?v=7Bo6LtNp-lo&trk=organization-update-content_share-embed-video_share-article_title